Answers are grounded in this paper and cite their sources.
In vitro findings show arylpiperazines improve selectivity and efficacy for α1-adrenoreceptors in LUTS/BPH therapies, suggesting acetophenone's role as a key ligand.
α 1-AR antagonists are currently first-line therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). In this study, we report the synthesis of a new series of arylpiperazine derivatives containing acetophenone (3-17) which possess α 1-adrenoreceptor blocking activity. The in vitro α 1-adrenoreceptor blocking activity of each derivative was first screened using rabbit thoracic aortic rings by measuring the relaxation response (%) activated by (–)-noradrenaline (3 μM). Compounds 6 and 7 with 2,5-dimethoxy and 2-ethoxy substituent were found to have significant vasodilatory effect. Since the presence of a chiral carbon in the structure, 6 and 7 together with their enantiomers 14-17 were further evaluated by testing diastolic effect on rabbit thoracic aorta, prostate and bladder smooth muscle. The S-enantiomer was found to have more potent diastolic activity than the R-enantiomer and racemate, 17 being the most effective α 1-adrenoreceptor antagonist. In order to assess tissue selectivity, the antagonistic effect of 17 on the (-)-noradrenaline induced contractile response of isolated rat vas deferens (α1A), spleen (α1B) and aorta (α1D) was characterized finally. Compared with naftopidil (1) and terazosin, compound 17 exhibited higher selectivity (18-fold) for the α1D-adrenoceptor subtype as compared to the α1B-adrenoceptor subtype, indicating less cardiovascular side effects for the treatment of LUTS/BPH. These data suggest that the acetophenone is a new effective adrenergic receptor ligand as well as incentivizes further research regarding pharmacological properties of chiral molecules.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: